Back to UBS Group AG UBS Group AG

BCLIBCLI
4 quarters

Position history for UBS Group AGUBS Group AG's holdings in BrainStorm Cell Therapeutics In

UBS Group AG previously held 0 shares of BCLI (BrainStorm Cell Therapeutics In), worth $0 as of 2025-Q3.

Final Value

$0

Final Shares

0

Total Value Change

-$7,881

Total Shares Change

-3,472

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q3
Latest
Exited
0
-100.0%
$00.0%$0.70
0
2025-Q2
Increased
12,380
+4793.3%
$13,8650.0%$1.06
20
2025-Q1
Decreased
253
-92.7%
$3190.0%$1.19
0
2024-Q4
New
3,472
-
$7,8810.0%$2.37
25

Other major holders of BCLI: VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used